Anavex Life Sciences Corp.
$3.65
▼
-3.55%
2026-04-21 05:30:01
www.anavex.com
NMS: AVXL
Explore Anavex Life Sciences Corp. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$338.25 M
Current Price
$3.65
52W High / Low
$13.99 / $2.61
Stock P/E
—
Book Value
$1.37
Dividend Yield
—
ROCE
-54.15%
ROE
-33.63%
Face Value
—
EPS
$-0.46
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
34
Beta
1.18
Debt / Equity
—
Current Ratio
20.87
Quick Ratio
11.6
Forward P/E
-21.07
Price / Sales
—
Enterprise Value
$141.63 M
EV / EBITDA
—
EV / Revenue
—
Rating
Strong Buy
Target Price
$22
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Immunovant, Inc. | $28.53 | — | $5.81 B | — | -61.93% | -69.35% | $29.48 / $13.36 | $4.85 |
| 2. | BioCardia, Inc. | $1.25 | — | $12.91 M | — | -843.83% | -9.5% | $3.2 / $1 | $0.08 |
| 3. | Impact BioMedical Inc. | $0.68 | — | $67.48 M | — | -26.29% | -1.04% | $1.95 / $0.36 | $0.12 |
| 4. | Nektar Therapeutics | $100.35 | — | $2.87 B | — | -57.64% | -2.18% | $109 / $7.99 | $4.41 |
| 5. | BridgeBio Pharma, Inc. | $74.02 | — | $14.41 B | — | -77.47% | 40.79% | $84.94 / $31.77 | $-10.71 |
| 6. | Cybin D/B/A Helus Pharma | $5.61 | — | $1.92 M | — | -60.35% | -55.89% | $12.7 / $5.9 | $5.49 |
| 7. | Elicio Therapeutics, Inc. | $12.2 | — | $224.43 M | — | -210.11% | 817.92% | $14.93 / $4.7 | $0.09 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -6.78 M | -11.48 M | -14.31 M | -12.42 M | -13.58 M | — |
| Net Profit | -5.68 M | -9.83 M | -13.24 M | -11.2 M | -12.11 M | — |
| EPS in Rs | -0.06 | -0.11 | -0.14 | -0.12 | -0.13 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -51.37 M | -52.8 M | -55.74 M | -50.99 M |
| Net Profit | -46.38 M | -43 M | -47.51 M | -47.98 M |
| EPS in Rs | -0.5 | -0.46 | -0.51 | -0.52 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 103.81 M | 135.57 M | 154.39 M | 152.71 M |
| Total Liabilities | 8.95 M | 15.3 M | 12.53 M | 10.21 M |
| Equity | 94.87 M | 120.26 M | 141.85 M | 142.49 M |
| Current Assets | 103.81 M | 135.57 M | 154.39 M | 152.71 M |
| Current Liabilities | 8.95 M | 15.3 M | 12.53 M | 10.21 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -39.04 M | -30.81 M | -27.79 M | -24.24 M |
| Investing CF | — | — | — | — |
| Financing CF | 9.43 M | 11.97 M | 29.65 M | 21.29 M |
| Free CF | -39.04 M | -30.81 M | -27.79 M | -24.24 M |
| Capex | — | — | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 9.48% | 0.99% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.